Annual CFO
-$34.24 M
-$2.83 M-8.99%
31 December 2023
Summary:
Candel Therapeutics annual cash flow from operations is currently -$34.24 million, with the most recent change of -$2.83 million (-8.99%) on 31 December 2023. During the last 3 years, it has fallen by -$25.17 million (-277.51%). CADL annual CFO is now -561.46% below its all-time high of -$5.18 million, reached on 31 December 2019.CADL Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$6.57 M
-$375.00 K-6.05%
30 September 2024
Summary:
Candel Therapeutics quarterly cash flow from operations is currently -$6.57 million, with the most recent change of -$375.00 thousand (-6.05%) on 30 September 2024. Over the past year, it has increased by +$2.23 million (+25.37%). CADL quarterly CFO is now -336.74% below its all-time high of -$1.50 million, reached on 30 September 2020.CADL Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$28.63 M
+$2.23 M+7.24%
30 September 2024
Summary:
Candel Therapeutics TTM cash flow from operations is currently -$28.63 million, with the most recent change of +$2.23 million (+7.24%) on 30 September 2024. Over the past year, it has increased by +$5.08 million (+15.06%). CADL TTM CFO is now -1193.18% below its all-time high of -$2.21 million, reached on 31 March 2020.CADL TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CADL Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.0% | +25.4% | +15.1% |
| 3 y3 years | -277.5% | +4.7% | -40.4% |
| 5 y5 years | - | - | - |
CADL Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -277.5% | at low | -25.5% | +39.3% | -40.4% | +16.5% |
| 5 y | 5 years | -561.5% | at low | -336.7% | +39.3% | -1193.2% | +16.5% |
| alltime | all time | -561.5% | at low | -336.7% | +39.3% | -1193.2% | +16.5% |
Candel Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.57 M(+6.1%) | -$28.63 M(-7.2%) |
| June 2024 | - | -$6.20 M(-26.5%) | -$30.87 M(-3.1%) |
| Mar 2024 | - | -$8.44 M(+13.7%) | -$31.86 M(-7.0%) |
| Dec 2023 | -$34.24 M(+9.0%) | -$7.42 M(-15.7%) | -$34.24 M(+1.6%) |
| Sept 2023 | - | -$8.81 M(+22.4%) | -$33.71 M(-1.7%) |
| June 2023 | - | -$7.20 M(-33.5%) | -$34.28 M(+0.3%) |
| Mar 2023 | - | -$10.82 M(+57.1%) | -$34.19 M(+8.8%) |
| Dec 2022 | -$31.42 M | -$6.88 M(-26.6%) | -$31.42 M(+5.5%) |
| Sept 2022 | - | -$9.38 M(+32.2%) | -$29.77 M(+9.1%) |
| June 2022 | - | -$7.10 M(-11.9%) | -$27.28 M(+10.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$8.05 M(+53.7%) | -$24.64 M(+10.9%) |
| Dec 2021 | -$22.22 M(+144.9%) | -$5.24 M(-24.0%) | -$22.22 M(+8.9%) |
| Sept 2021 | - | -$6.89 M(+54.6%) | -$20.40 M(+35.9%) |
| June 2021 | - | -$4.46 M(-20.8%) | -$15.01 M(+20.2%) |
| Mar 2021 | - | -$5.63 M(+64.7%) | -$12.48 M(+37.6%) |
| Dec 2020 | -$9.07 M(+75.2%) | -$3.42 M(+127.0%) | -$9.07 M(+60.4%) |
| Sept 2020 | - | -$1.50 M(-22.3%) | -$5.66 M(+36.3%) |
| June 2020 | - | -$1.94 M(-12.6%) | -$4.15 M(+87.4%) |
| Mar 2020 | - | -$2.21 M | -$2.21 M |
| Dec 2019 | -$5.18 M | - | - |
FAQ
- What is Candel Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Candel Therapeutics?
- What is Candel Therapeutics annual CFO year-on-year change?
- What is Candel Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Candel Therapeutics?
- What is Candel Therapeutics quarterly CFO year-on-year change?
- What is Candel Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Candel Therapeutics?
- What is Candel Therapeutics TTM CFO year-on-year change?
What is Candel Therapeutics annual cash flow from operations?
The current annual CFO of CADL is -$34.24 M
What is the all time high annual CFO for Candel Therapeutics?
Candel Therapeutics all-time high annual cash flow from operations is -$5.18 M
What is Candel Therapeutics annual CFO year-on-year change?
Over the past year, CADL annual cash flow from operations has changed by -$2.83 M (-8.99%)
What is Candel Therapeutics quarterly cash flow from operations?
The current quarterly CFO of CADL is -$6.57 M
What is the all time high quarterly CFO for Candel Therapeutics?
Candel Therapeutics all-time high quarterly cash flow from operations is -$1.50 M
What is Candel Therapeutics quarterly CFO year-on-year change?
Over the past year, CADL quarterly cash flow from operations has changed by +$2.23 M (+25.37%)
What is Candel Therapeutics TTM cash flow from operations?
The current TTM CFO of CADL is -$28.63 M
What is the all time high TTM CFO for Candel Therapeutics?
Candel Therapeutics all-time high TTM cash flow from operations is -$2.21 M
What is Candel Therapeutics TTM CFO year-on-year change?
Over the past year, CADL TTM cash flow from operations has changed by +$5.08 M (+15.06%)